Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

144 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Genomic and transcriptomic profiling of pre- and postneoadjuvant chemotherapy triple negative breast cancer tumors.
Nishimura T, Velaga R, Masuda N, Kawaguchi K, Kawaguchi S, Takada M, Maeshima Y, Tanaka S, Kikawa Y, Kadoya T, Bando H, Nakamura R, Yamamoto Y, Ueno T, Yasojima H, Ishiguro H, Morita S, Ohno S, Haga H, Matsuda F, Ogawa S, Toi M. Nishimura T, et al. Among authors: maeshima y. Cancer Sci. 2024 Dec;115(12):3928-3942. doi: 10.1111/cas.16339. Epub 2024 Oct 7. Cancer Sci. 2024. PMID: 39375938 Free PMC article.
Time-series blood cytokine profiles correlate with treatment responses in triple-negative breast cancer patients.
Saldajeno DP, Kawaoka S, Masuda N, Tanaka S, Bando H, Nishimura T, Kadoya T, Yamanaka T, Imoto S, Velaga RM, Tamura N, Aruga T, Ikeda K, Fukui Y, Maeshima Y, Takada M, Suzuki E, Ueno T, Ogawa S, Haga H, Ohno S, Morita S, Kawaguchi K, Toi M. Saldajeno DP, et al. Among authors: maeshima y. Br J Cancer. 2024 Apr;130(6):1023-1035. doi: 10.1038/s41416-023-02527-0. Epub 2024 Jan 18. Br J Cancer. 2024. PMID: 38238427
Comparison of cisplatin-based versus standard preoperative chemotherapy in patients with operable triple-negative breast cancer: propensity score matching and inverse probability of treatment weighting analysis.
Yamaguchi A, Kawaguchi K, Kawanishi K, Maeshima Y, Nakakura A, Kataoka TR, Takahara S, Nakagawa S, Yonezawa A, Takada M, Kawashima M, Kawaguchi-Sakita N, Kotake T, Suzuki E, Shimizu H, Torii M, Morita S, Ishiguro H, Toi M. Yamaguchi A, et al. Among authors: maeshima y. Breast Cancer Res Treat. 2024 Apr;204(2):261-275. doi: 10.1007/s10549-023-07163-z. Epub 2023 Dec 21. Breast Cancer Res Treat. 2024. PMID: 38123790 Free PMC article.
Intra-patient spatial comparison of non-metastatic and metastatic lymph nodes reveals the reduction of CD169+ macrophages by metastatic breast cancers.
Maeshima Y, Kataoka TR, Vandenbon A, Hirata M, Takeuchi Y, Suzuki Y, Fukui Y, Kawashima M, Takada M, Ibi Y, Haga H, Morita S, Toi M, Kawaoka S, Kawaguchi K. Maeshima Y, et al. EBioMedicine. 2024 Sep;107:105271. doi: 10.1016/j.ebiom.2024.105271. Epub 2024 Aug 21. EBioMedicine. 2024. PMID: 39173531 Free PMC article.
144 results